1. Home
  2. OSRH vs CVM Comparison

OSRH vs CVM Comparison

Compare OSRH & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OSR Holdings Inc.

OSRH

OSR Holdings Inc.

HOLD

Current Price

$0.38

Market Cap

17.9M

Sector

N/A

ML Signal

HOLD

Logo Cel-Sci Corporation

CVM

Cel-Sci Corporation

HOLD

Current Price

$1.02

Market Cap

21.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OSRH
CVM
Founded
N/A
1983
Country
United States
United States
Employees
22
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.9M
21.4M
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
OSRH
CVM
Price
$0.38
$1.02
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
928.1K
335.4K
Earning Date
05-19-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$264,033.00
Revenue This Year
$9.30
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
65.45
52 Week Low
$0.37
$0.89
52 Week High
$1.57
$13.48

Technical Indicators

Market Signals
Indicator
OSRH
CVM
Relative Strength Index (RSI) 37.04 30.33
Support Level N/A $0.89
Resistance Level $0.45 $1.59
Average True Range (ATR) 0.03 0.11
MACD 0.00 0.02
Stochastic Oscillator 10.64 3.49

Price Performance

Historical Comparison
OSRH
CVM

About OSRH OSR Holdings Inc.

OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea. The company's pipeline products include: Vaximm, Darnatein, Woori IO, and RMC.

About CVM Cel-Sci Corporation

CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.

Share on Social Networks: